Search clinical trials for: insulin 338 (GIPET I)

Total 56 results

Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Chong Kun Dang Pharmaceutical

Unknown

Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety Profile of CKD-333

Hypertension | Dyslipidemias

Korea, Republic of
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Yale University

Completed

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Type 1 Diabetes Mellitus

United States
University of Pittsburgh

Completed

Insulin Start Therapy Application With Resources and Training (I-START)

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. (DUAL™ I Japan)

Diabetes Mellitus, Type 2 | Diabetes

Japan
State University of Maringá
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Financiadora... and other collaborators

Completed

Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers

Wound | Pressure Ulcer
Sanofi

Terminated

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents (LixiLan-D)

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (Soli-CGM)

Type 2 Diabetes Mellitus

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
FDA Office of Orphan Products Development
Children's Hospital of Philadelphia

Completed

Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Hyperinsulinism
Children's Hospital of Philadelphia

Completed

Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Hyperinsulinism
Beth Israel Deaconess Medical Center

Completed

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

Hyperglycemia | Insulin Resistance

United States
Children's Hospital of Philadelphia

Completed

Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Hyperinsulinism
Consorzio Mario Negri Sud
Artsana SpA

Completed

Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm. (AGO01)

Type 1 Diabetes | Type 2 Diabetes

Italy
Becton, Dickinson and Company

Completed

Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles

Diabetes

United States
Bispebjerg Hospital
The Danish Medical Research Council

Unknown

Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I (IGF-I)

Tendinopathy

Denmark
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Gastric Cancer | Esophageal Cancer

United States
Novo Nordisk A/S

Withdrawn

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes
Martin Gutierrez
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Withdrawn

Selinexor Combination Ph 1 Study

Solid Tumor Malignancy

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Sarcoma | Lung Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
University of California, San Francisco
National Cancer Institute (NCI); Ipsen

Completed

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

High Grade Glioma

United States
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
South Plains Oncology Consortium

Recruiting

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Recurrent or Refractory Solid Tumors

United States
Montreal Heart Institute

Not yet recruiting

Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation (MILAN)

Right Ventricular Dysfunction | Right Heart Failure
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | Bone Marrow, Sympathetic Nervous System

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Adult Solid Neoplasm

United States
University of Southern California
National Cancer Institute (NCI); Ipsen

Withdrawn

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric Adenocarcinoma

United States
University Medical Centre Ljubljana
University of Ljubljana

Recruiting

The Effect of Combining Medium Cut Off Dialysis Membrane and Diet Modification on Reducing of Inflammation Response

End Stage Renal Disease | Chronic Inflammation | Diet, Healthy | Haemodialysis

Slovenia
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
GERCOR - Multidisciplinary Oncology Cooperative...
Merrimack Pharmaceuticals

Completed

A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer (DOUBLIRI)

Unresectable Advanced Cancer

France
The Third Xiangya Hospital of Central South University

Completed

Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori

Helicobacter Pylori Infection

China
Dong Bing Zhao

Recruiting

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Gastric Cancer | Neoadjuvant Therapy | Organoid

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

Recurrent Rectal Carcinoma | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Rectal Mucinous Adenocarcinoma | Rectal Signet Ring Cell Adenocarcinoma | Stage IIA Rectal Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Malignant Solid Neoplasm

United States
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States

Search clinical trials for: insulin 338 (GIPET I)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations